These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 9391522)

  • 21. Emerging issues in vaccine economics: perspectives from the USA.
    Lieu TA; Thompson KM; Prosser LA; O'Brien MA; Yusuf HR; Shefer AM; Weinstein MC; Rickert DL
    Expert Rev Vaccines; 2002 Dec; 1(4):433-42. PubMed ID: 12901581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    de Kok IM; van Ballegooijen M; Habbema JD
    J Natl Cancer Inst; 2009 Aug; 101(15):1083-92. PubMed ID: 19571256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conquering the intolerable burden of malaria: what's new, what's needed: a summary.
    Breman JG; Alilio MS; Mills A
    Am J Trop Med Hyg; 2004 Aug; 71(2 Suppl):1-15. PubMed ID: 15331814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Thai expanded programme on immunization: role of immunization sessions and their cost-effectiveness.
    Phonboon K; Shepard DS; Ramaboot S; Kunasol P; Preuksaraj S
    Bull World Health Organ; 1989; 67(2):181-8. PubMed ID: 2501043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose?
    Lopez AS; Guris D; Zimmerman L; Gladden L; Moore T; Haselow DT; Loparev VN; Schmid DS; Jumaan AO; Snow SL
    Pediatrics; 2006 Jun; 117(6):e1070-7. PubMed ID: 16740809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cost-effectiveness of pneumococcal conjugate vaccination in Australia.
    Butler JR; McIntyre P; MacIntyre CR; Gilmour R; Howarth AL; Sander B
    Vaccine; 2004 Mar; 22(9-10):1138-49. PubMed ID: 15003641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
    Reynales-Shigematsu LM; Rodrigues ER; Lazcano-Ponce E
    Arch Med Res; 2009 Aug; 40(6):503-13. PubMed ID: 19853192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rotavirus vaccination for Hong Kong children: an economic evaluation from the Hong Kong Government perspective.
    Ho AM; Nelson EA; Walker DG
    Arch Dis Child; 2008 Jan; 93(1):52-8. PubMed ID: 17855438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Controlling schistosomiasis: the cost-effectiveness of alternative delivery strategies.
    Guyatt H; Evans D; Lengeler C; Tanner M
    Health Policy Plan; 1994 Dec; 9(4):385-95. PubMed ID: 10139471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccination or mass drug administration against schistosomiasis: a hypothetical cost-effectiveness modelling comparison.
    Collyer BS; Turner HC; Hollingsworth TD; Keeling MJ
    Parasit Vectors; 2019 Oct; 12(1):499. PubMed ID: 31647019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The costs and a cost-benefit analysis of an S. mansoni control programme on an irrigated sugar estate in northern Tanzania.
    Fenwick A
    Bull World Health Organ; 1972; 47(5):573-8. PubMed ID: 4540676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cost-effectiveness and cost-benefit analysis on the integrated schistosomiasis control strategies with emphasis on infection source in Poyang Lake region].
    Lin DD; Zeng XJ; Chen HG; Hong XL; Tao B; Li YF; Xiong JJ; Zhou XN
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2009 Aug; 27(4):297-302. PubMed ID: 20066982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of a successful schistosomiasis control programme in Cambodia (1995-2006).
    Croce D; Porazzi E; Foglia E; Restelli U; Sinuon M; Socheat D; Montresor A
    Acta Trop; 2010 Mar; 113(3):279-84. PubMed ID: 19962364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Different approaches to modelling the cost-effectiveness of schistosomiasis control.
    Guyatt H
    Mem Inst Oswaldo Cruz; 1998; 93 Suppl 1():75-84. PubMed ID: 9921326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Workshop report: Schistosomiasis vaccine clinical development and product characteristics.
    Mo AX; Colley DG
    Vaccine; 2016 Feb; 34(8):995-1001. PubMed ID: 26721329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Different approaches to modeling the cost-effectiveness of schistosomiasis control.
    Guyatt HL; Tanner M
    Am J Trop Med Hyg; 1996 Nov; 55(5 Suppl):159-64. PubMed ID: 8940970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost analysis of schistosomiasis.
    Bundy DA; Guyatt HL
    Trans R Soc Trop Med Hyg; 1992; 86(6):646-8. PubMed ID: 1287932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human schistosomiasis: potential long-term consequences of vaccination programmes.
    Chan MS; Woolhouse ME; Bundy DA
    Vaccine; 1997 Oct; 15(14):1545-50. PubMed ID: 9330466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Operations research in schistosomiasis control.
    Davis A
    Trop Med Parasitol; 1989 Jun; 40(2):125-9. PubMed ID: 2672283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.